TFF Pharmaceuticals (TFFP) 10-K2022 FY Annual report

Filed: 31 Mar 23, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: allergy, anaphylactic, aplasia, Assistant, assumption, ATM, atopic, Augment, Avizakimab, big, Biology, borrow, borrowing, Boston, calcineurin, Catalent, categorized, CDMO, CEO, certainty, Children, Cogent, collateralized, consecutive, cooperation, doubt, earlier, economy, excise, explained, fallen, feedback, Fellowship, fraction, Genzyme, GlobalData, hematologic, hemolytic, hyperkalemia, immunogenicity, implicit, incremental, Inflation, ingredient, inhibitor, initialoption, injection, Intent, invented, IRA, IRS, Kiniksa, lymphoma, malignancy, maturity, Medial, microangiopathy, Mikhak, NIH, nondisparagement, nonsolicitation, Omicron, oversaw, partial, partly, Perla, pharma, photosensitivity, portfolio, pure, purpura, reaction, recoverability, red, regain, regimen, Residency, Sanofi, Societal, Southwest, spent, Subtopic, suppression, surcharge, Synteract, TAC, thrombocytopenic, thrombotic, travel, underway, underwritten, uremic, variability, variant, viral, visual, Vixarelimab, weaned, wholly, Zamaneh

Removed: accredited, actuated, Advair, Aeroneb, aforementioned, age, Agriculture, alter, anemia, anorexia, antifungal, anxiety, approach, Bill, blood, cannabidiol, chronic, cite, coma, commerce, confirmed, confusion, constipation, Cosmetic, CSA, cultivation, DEA, dependence, DESI, diarrhea, dietary, discovered, discussing, dispensing, dissolution, dissolving, distribute, distributing, divest, Dow, dozen, Dravet, eating, energy, entry, Epidiolex, epilepsy, excipient, exempt, explored, exporting, Farm, FASB, fasting, fluid, formula, galactose, grower, handle, hemp, hirsutism, immunocompromised, immunological, Immunosuppression, importation, importing, incorporate, indigestion, inflammation, insomnia, instance, interstate, intolerance, inventory, launch, legalize, liberalized, lowest, magnesium, marijuana, meantime, measurement, minimal, mirror, nausea, newly, notably, oil, older, optic, pain, papilledema, participated, passage, payroll, peripheral, port, potassium, prepare, processed, procurement, prophylactic, prospectively, pursued, quantified, refilled, regulated, reiterated, resale, revoke, rulemaking, scaled, scaling, scheduling, schizophrenia, separately, sesame, showed, sleep, stomach, strictest, suffering, supervision, susceptible, Symbicort, trehalose, typical, unpleasant, utilize, veterinary, weighted, white

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

TFFP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SS.1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of TFF Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Harlan Weisman, the Chief Executive Officer, and Kirk Coleman, the Chief Financial Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

By:	/s/ Harlan Weisman	Dated: March 31, 2023
	Harlan Weisman
Title:	Chief Executive Officer (Principal Executive Officer)

By:	/s/ Kirk Coleman	Dated: March 31, 2023
	Kirk Coleman
Title:	Chief Financial Officer (Principal Financial and Accounting Officer)

This certification is made solely for the purposes of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.